18 reports of this reaction
1.7% of all CALCIUM SULFATE ANHYDROUS reports
#9 most reported adverse reaction
ASTHENIA is the #9 most commonly reported adverse reaction for CALCIUM SULFATE ANHYDROUS, manufactured by DNA Labs, Inc.. There are 18 FDA adverse event reports linking CALCIUM SULFATE ANHYDROUS to ASTHENIA. This represents approximately 1.7% of all 1,039 adverse event reports for this drug.
Patients taking CALCIUM SULFATE ANHYDROUS who experience asthenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHENIA is a less commonly reported adverse event for CALCIUM SULFATE ANHYDROUS, but still significant enough to appear in the safety profile.
In addition to asthenia, the following adverse reactions have been reported for CALCIUM SULFATE ANHYDROUS:
The following drugs have also been linked to asthenia in FDA adverse event reports:
ASTHENIA has been reported as an adverse event in 18 FDA reports for CALCIUM SULFATE ANHYDROUS. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHENIA accounts for approximately 1.7% of all adverse event reports for CALCIUM SULFATE ANHYDROUS, making it a notable side effect.
If you experience asthenia while taking CALCIUM SULFATE ANHYDROUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.